

2022

Metreleptin

Genetics

Diagnosis

Subtypes

Discovery

New Treatments

Lipodystrophy

# Unlocking the metabolic code of lipodystrophy //

## A Global Summit

organised by Amryt Pharmaceuticals

>> RUNNYMEDE-ON-THAMES // EGHAM // SURREY // UNITED KINGDOM

3 >> 4 MAY >> 2022

Welcome to this Global Summit, organised by Amryt Pharmaceuticals, where we bring together physicians experienced in the treatment of congenital and acquired lipodystrophy (LD). The Global Summit will examine how LD scrambles patients' metabolism, resulting in a complex series of syndromes and symptoms that can be notoriously difficult to unlock.

We will hear from leaders in the field experienced in the diagnosis and treatment of LD, and hear about new initiatives that are providing the keys to diagnosis and treatment of these most complex of diseases.

We are privileged to welcome Jeffrey Friedman as a keynote speaker. Professor Friedman is credited with the discovery of the leptin gene – itself a crucial marker in LD diagnosis and treatment.

## >> DAY 1

Tuesday 3 MAY >> 2022



14:00

### Welcome and introductions

#### Diagnosis

14:00–14:30

#### Lipodystrophy overview

Stephen O’Rahilly (UK)

- History of the first diagnosis of LD
- Definition of lipodystrophy
- Presentation
- Differential diagnosis

#### Subtypes

14:30–15:00

#### Lipodystrophy subtypes

Corinne Vigouroux (France)

- GL and PL
- Uncommon variants (Madelung’s, progeria etc)
- Plans for a revised classification

#### Genetics

15:30–16:00

#### Clinical vs genetic diagnosis

Abhimanyu Garg (USA)

- Value of skinfolds and standard Dexa
- Can leptin levels help or will it cause more confusion?
- Role of genetic analysis: what approach?

#### Technology

16:00–16:30

#### New initiatives in diagnosis

David Araujo (Spain)  
Elif Oral (USA)

- Lipo-DDx app
- Fat shadows/MRI based imaging
- AI and machine learning

#### Natural history

17:00–17:30

#### Natural history of lipodystrophy

Rebecca Brown (USA)

- Overview of disease progression
- Mortality
- Treatment options
- Preventing the inevitable

#### Registries

17:30–18:00

#### Registry data

Julia von Schnurbein (Germany)  
Bariş Akıncı\* (Turkey)

- ECLip
- LD Lync
- Qualip

#### Scoring

18:00–18:30

#### Looking beyond HbA1c and TGs – development of an LD scoring tool

Bariş Akıncı\*



## &gt;&gt; DAY 2

Wednesday 4 MAY &gt;&gt; 2022

## Metreleptin (GL)

09:00–09:30

**Metreleptin in the management of generalized lipodystrophy (GL)**

Rebecca Brown

- NIH studies
- Looking beyond HbA1c and TGs

## Metreleptin (PL)

09:30–10:00

**Metreleptin in the management of partial lipodystrophy (PL)**

Elif Oral

- NIH studies
- Data in PL subgroups
- Requirement for low leptin levels in order for the patient to be a responder to treatment

## Populations

10:00–11:00

**Challenges of specific populations**Martin Wabitsch  
(Germany)

- Young children
- Elderly, kidney/liver dysfunction
- Pregnancy

Ferruccio Santini (Italy)

Rebecca Brown

## Case studies

11:30–12:15

**Coffee break****Case studies**Ingrid Jazet  
(The Netherlands)

Ann Mertens (Belgium)

Giovanni Ceccarini (Italy)

## Patient view

12:15–12:30

**Lipodystrophy and metreleptin – the patient perspective**

Elena Recio (Spain)

## New treatments

12:30–13:00

**New horizons – treatments in development**

Elif Oral

## Keynote

13:00–13:30

**Discovery and evolution of the role of leptin**

Jeffrey Friedman (USA)

13:30

**Meeting close**

## Meeting room

**Grand Union 1&2**

## Hotel information

Dinner will be held on **Tuesday 3 May** from 19:30–23:00 in the Grand Union 1&2.

Breakfast is served from 06:30–10:30 in the Leftbank Restaurant.

Internet is available throughout the hotel for guests.

Check out by 11:00 on the day of departure.

## Need help?

For questions relating to the meeting, please contact:

**Ann Marie Eastmond** or **Kate Siddall** on the Welcome Desk.



**Amryt Pharmaceuticals DAC.**  
**45 Mespil Road, Dublin 4, Ireland**

Tel: **+44 1604 549 952**  
**00 800 4447 4447**

Email: **Medinfo@amrytpharma.com**

©Amryt Pharmaceuticals DAC 2022

C-LD/ALL/0006 | Date of preparation March 2022

This meeting is funded and organised by Amryt Pharmaceuticals DAC